arrow
S

Stéphanie Gaillard

Johns Hopkins School of Medicine
H指数:36
被引数:5,280

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B7-H4‒directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors: the Phase 1/2a (BLUESTAR), first-in-human study

B7-H4靶向抗体药物偶联物AZD8205(puxitatug samrotecan)在晚期/转移性实体瘤患者中的I/IIa期(BLUESTAR)首次人体研究

2026-10-300
OAAI
Cervical Cancer, Version 2.2026

Abu-Rustum, N.R.; Campos, S.M.; Amarnath, S.; Arend, R.; Barber, E.; Bradley, K.; Brooks, R.; Chino, J.; Chon, H.S.; Crispens, M.A. 宫颈癌,版本2.2026,NCCN肿瘤学临床实践指南。J. Natl. Compr. Cancer Netw. 2025, 23, 549–573. [Google Scholar] [CrossRef]

2025-12-010
PRE
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer

一项关于HPV16 L2E7E6融合蛋白疫苗接种后治疗HPV16+宫颈癌的随机试点研究

2025-08-200
PRE
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability

子宫内膜癌中lenvatinib与pembrolizumab联合应用的评估;一项关于实践模式、有效性和耐受性的真实世界多机构回顾。

2025-08-140
PRE
Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis

局部晚期宫颈癌的诱导化疗后序贯化放疗:一项系统评价和Meta分析

2025-05-160
PRE
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study

基因组改变、分子靶向治疗与生存:一项真实世界子宫内膜癌分子靶向治疗联盟队列研究

2025-05-010
PRE
A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era

2024年国家癌症研究所/妇科癌症指导委员会子宫内膜癌临床试验规划会议工作组报告:在免疫治疗时代完善子宫内膜癌的治疗方法

2025-04-110
PRE
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer

曲美木单抗单药或联合奥拉帕尼治疗复发性上皮性卵巢癌的临床研究

2025-03-010
PRE
Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors

B7-H4靶向抗体药物偶联物(ADC)AZD8205(puxitatug samrotecan)在晚期/转移性实体瘤患者中的首次人体研究的初步结果

2024-09-011
PRE
Vulvar Cancer, Version 3.2024
2024-03-0112
OA
Cervical Cancer, Version 1.2024 Featured Updates to the NCCN Guidelines

宫颈癌,1.2024版更新了NCCN指南

2023-12-0165
OA
Transforming ovarian cancer care by targeting minimal residual disease

通过针对最小残留疾病转变卵巢癌护理

MED
IF11.8
2023-11-011
OAAI
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer
2023-04-2520
OA